CX Institutional’s Roivant Sciences ROIV Stock Holding History

CX Institutional’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Buy	628 +2	+0.3%	+$59	﹤0.01%	1158
2026 Q1	$17K	Buy	+626	New	+$16.1K	﹤0.01%	1165

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

CX Institutional's ROIV Position: Q2 2026 in Review

CX Institutional increased its Roivant Sciences (ROIV) stake by 0.32% in Q2 2026, buying an estimated $59 and bringing the position to 628 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

CX Institutional first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

CX Institutional held 628 shares of Roivant Sciences worth $22K as of Q2 2026.
CX Institutional bought 2 Roivant Sciences shares in Q2 2026, an estimated $59.
Roivant Sciences made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1158 holding.
CX Institutional first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.